Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
Jochen H LorchDana Farber Cancer institute, Boston, MA, USAAbstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCH...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-11-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/role-of-egf-inhibitors-in-the-treatment-of-recurrent-or-metastatic-squ-a3689 |
| Summary: | Jochen H LorchDana Farber Cancer institute, Boston, MA, USAAbstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments. Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor |
|---|---|
| ISSN: | 1179-1322 |